Stock comparison
LeMaitre Vascular
Takeda Pharmaceutical Company Limited
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
LMAT
LeMaitre Vascular
Market cap
$2.23B
Sector
Healthcare
TAK
Takeda Pharmaceutical Company Limited
Market cap
$51.34B
Sector
Healthcare
Overall winner
LeMaitre Vascular LMAT
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | LMAT | TAK | Winner |
|---|---|---|---|
| Warren Buffett | 77B | 44D | LMAT |
| Benjamin Graham | 89A | 56C | LMAT |
| Philip Fisher | 81C | 40D | LMAT |
| Peter Lynch | 67B | 18F | LMAT |
| Joel Greenblatt | 56D | 32F | LMAT |
| Charlie Munger | 68D | 41D | LMAT |
| Terry Smith | 69D | 36D | LMAT |
Side-by-side metrics
| Metric | LMAT | TAK |
|---|---|---|
| Market cap | $2.23B | $51.34B |
| P/E (TTM) | 37.1x | 43.0x |
| EV/EBIT | 36.6x | 22.0x |
| ROIC (TTM) | 9.43% | 2.59% |
| Gross margin | 72.39% | 58.76% |
| Net margin | 24.35% | 4.26% |
| Revenue CAGR 5y | 12.75% | 7.56% |
| EPS CAGR 5y | 19.04% | -3.46% |
| Debt / Equity | 0.5x | 0.6x |
| Dividend yield | 0.84% | 3.79% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
LMAT leads on
- EPS CAGR 5y19.04%vs -3.46%+118%
- Net margin24.35%vs 4.26%+83%
- ROIC (TTM)9.43%vs 2.59%+73%
- Revenue CAGR 5y12.75%vs 7.56%+41%
TAK leads on
- Market cap$51.34Bvs $2.23B+96%
- Dividend yield3.79%vs 0.84%+78%
- EV/EBIT22.0xvs 36.6x+40%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.